Navigation Links
NovoBioPharma, Partnership of Top Life Science Experts, Launches
Date:6/11/2013

CAMBRIDGE, Mass., June 11, 2013 /PRNewswire/ -- NovoBioPharma, a partnership of experts collaborating with life science organizations to provide comprehensive medical, scientific, regulatory, business and financial advisory services, launched today. The global business is comprised of four principals, all experts in their fields, who partnered to create an entity to help life science companies and institutions to cost-efficiently advance drug, diagnostic and device candidates by leveraging opportunities from conception through clinical development, and ultimately, regulatory approval.

With decades of experience and a global network in all areas of business, finance, drug, diagnostic and device development, NovoBioPharma offers services in capital sourcing and management, business development, intellectual property, quality control, manufacturing, study design, and protocol development. Simply put, NovoBioPharma covers every facet of the risky and costly work of developing life science breakthroughs.

The NovoBioPharma team is:

Bernie Rudnick, MBA, Chief Business Officer, is founder and managing partner of CapGenic Advisors, LLC, and a founding member of several Angel investing groups. Mr. Rudnick has substantial experience investing and guiding investments in entrepreneurial companies; he has led capital formation totaling more than $530 million in the past ten years and $3B during the last 15 years. Mr. Rudnick, a serial entrepreneur, founded, managed and advised numerous companies in the life sciences, including diagnostic, therapeutic and clinical software environments.  Mr. Rudnick is experienced in forms of capital formation including angel networks, venture capital funds, SBIR and other government grant programs. He is a graduate of Penn State and Northwood University.

Ira Wallace, MD, MBA is Chief Development Officer for NovoBioPharma. Dr. Wallace has been involved in pharmaceutical, biotech and medical device companies as a CEO, founder, board member and consultant.  In addition, Dr. Wallace is experienced in technology transfer and intellectual property strategies and is a founding member and partner in a number of Angel investment groups. A graduate of the University of Pennsylvania, Dr. Wallace earned his medical degree at Drexel Medical School and his MBA at Columbia.

Shahin Gharakhanian MD, Head, Pharmaceutical Medicine, is an infectious diseases and internal medicine trained physician with over 20 years experience in the pharmaceutical industry and clinical practice. His last position was Vice President in the Medicines Development Group/Global R&D at Vertex Pharmaceuticals, Inc. Cambridge MA, USA. In industry, Dr. Gharakhanian has driven: strategic leadership, clinical development and medical affairs. Overall, he has handled projects for twelve different pharmaceutical companies, ten different brands and four drug launches in Asia, Canada, EU and the United States. His most recent major New Drug Application/launch experience was in 2011. Dr. Gharakhanian earned his specialty medical degrees at University of Paris, and trained/practiced in AP-HP, Paris, France, the largest hospital system in Europe and one of the largest in the world.

Andrew D. Luber, PharmD Chief Scientific Officer, is an infectious diseases trained clinical pharmacist/pharmacologist with over 18 years experience working with the pharmaceutical industry as an investigator, key opinion leader, speakers bureau, steering committee and advisory board member.  In addition, he has served as a clinical consultant to large and early stage pharmaceutical companies.  Dr. Luber has been an investigator in more than 70 clinical trials including four Phase 1a first in human studies and specializes in early stage drug development. Dr. Luber received his doctor of pharmacy at Temple University and did his post-doctoral residencies and research fellowship at the University of California, San Francisco Medical Center and School of Pharmacy.

For more information, visit the website at NovoBioPharma
Contact:  Andrew D. Luber, PharmD 1-856-258-0850


'/>"/>
SOURCE NovoBioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis and Medicines360 Announce Partnership to Advance Womens Access to Affordable IUDs
2. Elekta-Equra Health Partnership to Increase South African Cancer Patients Access to Radiation Therapy
3. AmeriCares Honors Merck with Power of Partnership Award
4. PDR Network and OPTIMIZERx (SampleMD) Announce Partnership to Deliver Patient Financial Support Programs Within EHR Workflow
5. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
6. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
7. Life Line Screening and MCM Solutions for Better Health Announce New Partnership
8. United Way and FamilyWize Partnership Has Helped 5 Million People Stay Healthy
9. Allergans Global Dominance in Facial Injectables Challenged by Acquisitions and Partnership Agreements Among Competitors
10. Partnership Formed to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments
11. Huahai and Oncobiologics Create Broad Biosimilars Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... , ... Ridgecrest Herbals makes it a point to lead the Utah supplement ... support renewable energy. They believe this is a crucial part of their mission as ... issues, and maintain that destroying the environment in the pursuit of profit is unsustainable ...
(Date:4/24/2017)... ... 2017 , ... The bar for just about everything—apparel, eyewear, cars and even ... of pop and film stardom.(1) Not to be left out is that most desired ... run the gamut from being encrusted with jewels and precious metals to, at the ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Sean Fay ... Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold ... any other marketer in the last 25 years. , Now, due to changes in ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP Nutrition®, a ... announced its popular products are now available for purchase on StackedNutrition.com, a popular ... use of premium natural ingredients in making all of its products. These ingredients ...
Breaking Medicine News(10 mins):